Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA
12:23pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
09:50pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.89, marking a -0.67% move from the previous day.
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
04:12pm, Monday, 18'th Apr 2022 Zacks Investment Research
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
02:55pm, Monday, 18'th Apr 2022 Zacks Investment Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
05:34pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
Halozyme (HALO) to Acquire Antares for Auto Injector Platform
02:06pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.
M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus
02:03pm, Thursday, 14'th Apr 2022 Zacks Investment Research
We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates fo
Here's What This Regulatory News Could Mean for GlaxoSmithKline
11:08am, Thursday, 14'th Apr 2022 The Motley Fool
GlaxoSmithKline's anemia of chronic kidney disease drug could be just months away from authorization in the European Union.
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
09:45pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed the most recent trading day at $46.85, moving +0.69% from the previous trading session.
Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug
02:18pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.
Why Sierra Oncology Stock Is Soaring Today
12:14pm, Wednesday, 13'th Apr 2022 The Motley Fool
GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
06:36am, Wednesday, 13'th Apr 2022 MarketWatch
Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
03:20pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
This Exciting Biotech Stock Could Be Your Next 10-Bagger
10:00am, Sunday, 10'th Apr 2022 The Motley Fool
The company's drug development program is the major key to success.
